Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Indazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.76 |
| ▸ | IDO1 | P14902 | 1/20 | 0.76 |
| ▸ | CDK2 | P24941 | 1/20 | 0.76 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | CLK3 | P49761 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indazole SCHEMBL27577839 | 0.92 | HSP90AA1 (0.70) | HSP90AA1IDO1CDK2ABCB1ALDH1A1 | |
| Indazole SCHEMBL5222669 | 0.89 | HSP90AA1 (0.66) | HSP90AA1IDO1CDK2ABCB1ALDH1A1 | |
| Indazole SCHEMBL6168428 | 0.88 | HSP90AA1 (0.76) | HSP90AA1IDO1CDK2ABCB1ALDH1A1 | |
| Indazole SCHEMBL29208977 | 0.88 | HSP90AA1 (0.76) | HSP90AA1IDO1CDK2ABCB1ALDH1A1 | |
| Indazole SCHEMBL29355507 | 0.87 | — | — | |
| Indazole SCHEMBL1221882 | 0.87 | HSP90AA1 (1.00) | HSP90AA1IDO1CDK2ABCB1ALDH1A1 | |
| Indazole SCHEMBL6295 | 0.87 | — | — | |
| Indazole SCHEMBL8415085 | 0.86 | HSP90AA1 (0.79) | HSP90AA1IDO1CDK2ABCB1ALDH1A1 | |
| Indazole SCHEMBL20985592 | 0.85 | HSP90AA1 (0.86) | HSP90AA1IDO1CDK2ABCB1ALDH1A1 | |
| Indazole SCHEMBL27982546 | 0.85 | HSP90AA1 (0.86) | HSP90AA1IDO1CDK2ABCB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105061317-B | One class indazole salt compounds and its preparation method and application | 浙江大果生物医药科技有限公司 | 2017-08-25 | — | — | CN | disclosed |
| CN-105061317-A | Indazole salt compound and preparing method and application thereof | ZHEJIANG DAGUO BIOLOG PHARMACEUTICAL CO LTD | 2015-11-18 | — | — | CN | disclosed |
| EP-1968594-A2 | TREATMENT OF OCULAR NEOVASCULAR DISORDERS SUCH AS MACULAR DEGENERATION, ANGIOD STREAKS, UVEITIS AND MACULAR EDEMA | SmithKline Beecham Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1954281-A2 | CANCER TREATMENT METHOD | SmithKline Beecham Corporation (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007143483-A2 | COMBINATION OF PAZOPANIB AND LAPATINIB FOR TREATING CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-13 | — | — | WO | disclosed |
| EP-1828182-A2 | THERAPEUTIC PYRAZOLO[3,4-B]PYRIDINES AND INDAZOLES | Warner-Lambert Company LLC (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007064753-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064752-A2 | TREATMENT OF OCULAR NEOVASCULAR DISORDERS SUCH AS MACULAR DEGENERATION, ANGIOD STREAKS, UVEITIS AND MACULAR EDEMA | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2006056873-A2 | THERAPEUTIC PYRAZOLO[3,4-B] PYRIDINES AND INDAZOLES | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-01 | — | — | WO | disclosed |
| EP-1515955-A4 | CHEMICAL PROCESS | SMITHKLINE BEECHAM CORP (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2006020564-A1 | PYRIMIDIN DERIVATIVES FOR THE TREATMENT OF MULTIPLE MYELOMA | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-1515955-A2 | CHEMICAL PROCESS | SmithKline Beecham Corporation (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003106416-A2 | CHEMICAL PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-24 | — | — | WO | disclosed |